📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore
Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.
Key Highlights
Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.
Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.
Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.
Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.
The acquisition is expected to be finalized within an indicative period of 30 days.
💼 Action for Investors
Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.
Jubilant Ingrevia Q3 FY26: 9% Volume Growth, INR 2.5 Interim Dividend, EBITDA at INR 136 Cr
Jubilant Ingrevia reported stable Q3 FY26 revenue of INR 1,051 crore, supported by a 9% year-on-year volume growth that offset softer global pricing. The company declared an interim dividend of 250% (INR 2.5 per share) and highlighted a robust opportunity funnel of over 100 projects with a peak revenue potential of INR 3,500 crore. While quarterly EBITDA dipped 8% to INR 136 crore due to pricing headwinds, the 9-month EBITDA rose 8% to INR 436 crore. Management expects growth to accelerate in Q4 FY26, driven by the commencement of a major CDMO order and new capacity expansions.
Key Highlights
Achieved 9% YoY volume growth in Q3 FY26, marking the second-highest volumes in the last 12 quarters.
Declared an interim dividend of 250%, translating to INR 2.5 per equity share.
Specialty Chemicals segment maintained resilient margins above 25% despite intense global pricing pressure.
Secured 16 new molecule wins during the year with an estimated peak revenue potential of INR 1,400 crore.
Renewable energy share increased to 34%, contributing to a 10% YoY reduction in power and fuel expenses.
💼 Action for Investors
Investors should focus on the company's transition toward high-margin CDMO and specialty segments, with Q4 FY26 being a critical period for new order execution. The stock is a 'Watch' for signs of recovery in global chemical pricing which could further boost EBITDA margins.
Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.
Key Highlights
Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.
Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.
CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.
The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.
Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.
💼 Action for Investors
Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.
Jubilant Ingrevia Q3 FY26: PAT Drops 32% to ₹47 Cr; Declares ₹2.5 Interim Dividend
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue declining 1% YoY to ₹1,051 crore and PAT falling 32% to ₹47 crore, largely impacted by a one-time exceptional expense related to labor code amendments and global pricing pressures. Despite the bottom-line hit, the company maintained stable EBITDA margins of 13% and declared an interim dividend of ₹2.5 per share. Management highlighted a robust opportunity funnel of over ₹3,500 crore and the upcoming commencement of a major CDMO order in Q4 FY26. Volume growth across Specialty Chemicals and Nutrition segments helped offset softer global pricing.
Key Highlights
Revenue for Q3 FY26 stood at ₹1,051 crore, a marginal 1% YoY decline due to global pricing pressures.
EBITDA for the quarter was ₹136 crore with a stable margin of 13%, while 9M FY26 EBITDA rose 8% YoY.
The Board declared an interim dividend of 250% amounting to ₹2.5 per equity share.
Specialty Chemicals segment maintained a strong EBITDA margin of 25% despite pricing volatility in Pyridine.
CDMO pipeline expanded to over 100 opportunities with a peak annual revenue potential of ₹3,500 crore.
💼 Action for Investors
Investors should monitor the execution of the major CDMO order starting Q4 FY26 and the stabilization of global chemical pricing. While short-term earnings are under pressure, the strong expansion pipeline and dividend payout offer some support for long-term holders.
Jubilant Ingrevia Declares Interim Dividend of Rs 2.50 Per Share; Record Date Feb 10
Jubilant Ingrevia Limited has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. This dividend is applicable to shares with a face value of Re 1 each. The company has designated February 10, 2026, as the record date for identifying eligible shareholders. Shareholders can expect the dividend payment or dispatch to occur on or before March 4, 2026.
Key Highlights
Interim dividend of Rs 2.50 per equity share (250% of face value).
Record date for dividend eligibility set for February 10, 2026.
Dividend payment to be completed on or before March 4, 2026.
Board meeting concluded on February 4, 2026, to approve the payout.
💼 Action for Investors
Existing shareholders should ensure they hold the stock before the ex-dividend date to qualify for the Rs 2.50 payout. New investors may consider the dividend yield relative to the current stock price.
Jubilant Ingrevia Declares ₹2.50 Interim Dividend and Re-appoints Independent Director
Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26, representing a 250% payout on the face value of ₹1. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 17, 2026. This dual announcement reflects a commitment to both shareholder returns and leadership continuity.
Key Highlights
Interim dividend of ₹2.50 per equity share of ₹1 face value declared for FY 2025-26
Record date for dividend eligibility set for February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, with all items approved
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the February 10 record date. The re-appointment of an experienced director like Ms. Chatterjee is a positive sign for corporate governance stability.
Jubilant Ingrevia Declares ₹2.50 Interim Dividend; Sets Feb 10 as Record Date
Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to shareholders on or before March 4, 2026.
Key Highlights
Interim dividend declared at ₹2.50 per equity share of face value ₹1 each
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Re-appointment of Ms. Ameeta Chatterjee as Independent Director for a 5-year term until April 2031
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the Feb 10 record date. The re-appointment of an experienced independent director signals management stability.
Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Sets Feb 10 as Record Date
Jubilant Ingrevia has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board has approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to eligible shareholders by March 4, 2026.
Key Highlights
Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded at 5:15 PM on February 4, 2026
💼 Action for Investors
Investors looking to benefit from the dividend should ensure they hold the stock before the ex-dividend date. The re-appointment of an experienced independent director provides continuity in corporate governance.
Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Re-appoints Independent Director
Jubilant Ingrevia's Board has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to identify eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. This dual announcement highlights both a commitment to shareholder returns and leadership continuity.
Key Highlights
Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, at 05:15 p.m.
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the record date of February 10, 2026. The re-appointment of an experienced director is a positive sign for corporate governance stability.
Jubilant Ingrevia Q3 FY26 Net Profit Dips 5.6% YoY to ₹65.4 Crore; Revenue Flat
Jubilant Ingrevia reported a consolidated net profit of ₹65.41 crore for Q3 FY26, a 5.6% decline from ₹69.30 crore in the same quarter last year. Revenue from operations remained stagnant at ₹1,050.99 crore compared to ₹1,056.77 crore YoY. Sequentially, the company saw a 6.2% drop in revenue and a 5.8% decline in profit compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains stronger than the previous year, with PAT up 21% at ₹209.65 crore.
Key Highlights
Consolidated Net Profit for Q3 FY26 stood at ₹65.41 crore vs ₹69.30 crore YoY.
Total Revenue from operations was ₹1,050.99 crore, showing a marginal decline of 0.5% YoY.
Nutrition & Health Solutions segment grew by 5.9% YoY to ₹200.76 crore.
Speciality Chemicals segment revenue declined slightly to ₹457.57 crore from ₹467.64 crore YoY.
Nine-month (9M FY26) PAT increased significantly to ₹209.65 crore from ₹172.90 crore in 9M FY25.
💼 Action for Investors
The quarterly results indicate a temporary slowdown in the Speciality Chemicals and Intermediates segments. Investors should hold for long-term recovery while monitoring global chemical pricing trends and margin stability.
Jubilant Ingrevia Q2 FY26 Standalone Net Profit Drops 27% YoY to ₹44 Cr; Revenue Up 5%
Jubilant Ingrevia reported a standalone revenue of ₹1,054.18 crore for Q2 FY26, marking a 4.8% increase compared to ₹1,005.39 crore in the same quarter last year. However, net profit witnessed a significant decline of 26.8% YoY, falling to ₹44.03 crore from ₹60.18 crore, primarily due to margin pressure in the Chemical Intermediates segment which reported a loss. While the Speciality Chemicals segment showed robust EBIT growth of 46% YoY, the overall performance was weighed down by an 8% increase in total expenses.
Key Highlights
Standalone Revenue from operations grew 4.8% YoY to ₹1,054.18 crore in Q2 FY26.
Net Profit declined 26.8% YoY to ₹44.03 crore, down from ₹60.18 crore in Q2 FY25.
Speciality Chemicals segment EBIT rose significantly to ₹95.88 crore from ₹65.64 crore YoY.
Chemical Intermediates segment reported an EBIT loss of ₹14.04 crore compared to a profit of ₹30.53 crore in the previous year.
Total expenses increased to ₹1,005.63 crore, driven by higher raw material consumption and power costs.
💼 Action for Investors
Investors should remain cautious as the Chemical Intermediates segment has turned loss-making, impacting overall profitability despite growth in Speciality Chemicals. Monitor the company's ability to pass on raw material price increases in upcoming quarters.